Guardion Health Sciences (GHSI) Competitors $3.22 -0.07 (-2.13%) (As of 10/30/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends GHSI vs. HEPA, CLSN, BGXX, MRNS, CARA, TENX, SYBX, APRE, MTEX, and INABShould you be buying Guardion Health Sciences stock or one of its competitors? The main competitors of Guardion Health Sciences include Hepion Pharmaceuticals (HEPA), Imunon (CLSN), Bright Green (BGXX), Marinus Pharmaceuticals (MRNS), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Synlogic (SYBX), Aprea Therapeutics (APRE), Mannatech (MTEX), and IN8bio (INAB). These companies are all part of the "medical" sector. Guardion Health Sciences vs. Hepion Pharmaceuticals Imunon Bright Green Marinus Pharmaceuticals Cara Therapeutics Tenax Therapeutics Synlogic Aprea Therapeutics Mannatech IN8bio Guardion Health Sciences (NASDAQ:GHSI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media favor GHSI or HEPA? In the previous week, Guardion Health Sciences' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score. Company Overall Sentiment Guardion Health Sciences Neutral Hepion Pharmaceuticals Neutral Do analysts prefer GHSI or HEPA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Guardion Health Sciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Hepion Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, GHSI or HEPA? Guardion Health Sciences has higher revenue and earnings than Hepion Pharmaceuticals. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGuardion Health Sciences$12.25M0.35$160K$4.870.66Hepion PharmaceuticalsN/AN/A-$48.93M-$4.38-0.16 Do insiders and institutionals hold more shares of GHSI or HEPA? 20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by insiders. Comparatively, 2.0% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is GHSI or HEPA more profitable? Guardion Health Sciences has a net margin of 22.79% compared to Hepion Pharmaceuticals' net margin of 0.00%. Guardion Health Sciences' return on equity of -73.69% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Guardion Health Sciences22.79% -73.69% -48.17% Hepion Pharmaceuticals N/A -812.56%-207.31% Which has more volatility and risk, GHSI or HEPA? Guardion Health Sciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Does the MarketBeat Community favor GHSI or HEPA? Guardion Health Sciences received 41 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. However, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 67.39% of users gave Guardion Health Sciences an outperform vote. CompanyUnderperformOutperformGuardion Health SciencesOutperform Votes6267.39% Underperform Votes3032.61% Hepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% SummaryGuardion Health Sciences beats Hepion Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Guardion Health Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GHSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHSI vs. The Competition Export to ExcelMetricGuardion Health SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35M$6.50B$5.09B$8.81BDividend Yield155.28%8.11%5.04%4.07%P/E Ratio0.665.4594.6014.18Price / Sales0.35373.721,217.5288.10Price / Cash23.1552.5939.4936.27Price / Book0.5010.266.956.35Net Income$160,000.00$153.22M$118.83M$225.71M7 Day PerformanceN/A-1.74%-1.52%-0.32%1 Month Performance-1.15%-7.22%-3.39%1.76%1 Year Performance-42.50%31.69%32.17%27.70% Guardion Health Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHSIGuardion Health SciencesN/A$3.22-2.1%N/A-43.4%$4.35M$12.25M0.6610Gap DownHEPAHepion PharmaceuticalsN/A$0.71+1.5%N/A-78.1%$4.91MN/A0.0020CLSNImunonN/AN/AN/AN/A$13.91M$500,000.000.0027Analyst ForecastBGXXBright GreenN/A$0.09+5.4%N/A-78.4%$17.15MN/A-1.422News CoverageGap DownMRNSMarinus Pharmaceuticals4.4503 of 5 stars$0.31-0.2%$4.79+1,451.8%-95.0%$17.02M$30.99M-0.13110Analyst ForecastAnalyst RevisionGap DownCARACara Therapeutics3.7192 of 5 stars$0.30-0.2%$2.32+661.9%-71.2%$16.71M$20.97M-0.1855Analyst ForecastTENXTenax Therapeutics2.7706 of 5 stars$4.88+2.3%$16.00+227.9%-83.5%$16.64MN/A0.009Analyst RevisionNews CoveragePositive NewsSYBXSynlogic2.7524 of 5 stars$1.39-3.8%$30.00+2,058.3%-30.5%$16.26M$3.37M-0.356Positive NewsAPREAprea Therapeutics3.3831 of 5 stars$2.92-3.0%$15.50+430.8%-22.4%$15.86M$580,000.000.007Analyst ForecastAnalyst RevisionGap DownMTEXMannatech0.936 of 5 stars$8.40+4.3%N/A-15.5%$15.79M$131.96M0.00250Analyst ForecastGap UpHigh Trading VolumeINABIN8bio2.7424 of 5 stars$0.33+3.6%$7.75+2,227.3%-62.8%$15.58MN/A0.0020 Related Companies and Tools Related Companies HEPA Competitors CLSN Competitors BGXX Competitors MRNS Competitors CARA Competitors TENX Competitors SYBX Competitors APRE Competitors MTEX Competitors INAB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GHSI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardion Health Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardion Health Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
